Findings

What do systematic reviews say?

22 questions · 22 findings · 2 reviews

No studies found 6 · 27.3%GRADE not reported 0 · 0%Very low 7 · 31.8%Low 4 · 18.2%Moderate 5 · 22.7%High 0 · 0%

Overall discontinuation ( · patients with managing transfusional iron overload in people with sickle cell disease

Deferasirox may leads to lower discontinuations compared with deferoxamine (low certainty).

1 finding from 1 review

Deferasirox for managing transfusional iron overload in people with sickle cell disease 2014 · Cochrane Headline outcomes only
RR 0.53 [0.31, 0.92]
2 studies · 398 participants
Low

Satisfaction · patients with managing transfusional iron overload in people with sickle cell disease

Deferasirox probably leads to higher satisfaction compared with deferoxamine (moderate certainty).

1 finding from 1 review

Deferasirox for managing transfusional iron overload in people with sickle cell disease 2014 · Cochrane Headline outcomes only
RR 3.13 [1.99, 4.93]
1 study · 195 participants
Moderate